Skip to main content

Table 3 Reporting method of FEV 1 for all included trials for each scale (liter or % of predicted) and statistical method of reporting, at baseline (T 0 ) and endpoint (T e )

From: A systematic review with attempted network meta-analysis of asthma therapy recommended for five to eighteen year olds in GINA steps three and four

Scale of FEV1 Outcome summary measure Reference number of study reporting summary measure at T0 a Reference number of study reporting summary measure at Te b
Liter Mean   13, 15, 19
  Mean change   10, 14, 18
  Mean + SE or SD 8, 10, 11, 16, 18, 22, 23 8, 16
  Mean change + SE or SD   23
  Mean + range 14, 15, 16, 19 16
  P-value versus another arm   10, 14, 15, 18, 19, 23
  Difference between arms + 95%CI   13, 23
% of predicted Mean   13
  Mean change   11, 12, 18
  Mean + SE or SD 2, 3, 5, 6, 7, 9, 10, 11, 16, 17, 18, 20, 21, 22 2, 3, 6, 7, 9, 16, 17, 20
  Mean change + SE or SD   
  Mean + range 12, 13, 14, 15, 16, 17, 19 16
  P-value versus another arm   11, 12, 18
  Difference between arms + 95%CI   13, 17
  1. aT0 = baseline of the trial.
  2. bTe = endpoint of the trial, varying from 4 to 56 weeks.
  3. Reporting method of all included trials for each scale (litre or % of predicted) and statistical method of reporting, at baseline (T0) and endpoint (Te).